Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Shire gains exclusive license option to Heptares antagonist
June 2011
SHARING OPTIONS:

WELWYN GARDEN CITY, U.K.Heptares Therapeutics has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist that Heptares discovered and currently has in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) implicated in regulating dopaminergic pathways in the brain, and inhibition of the receptor has recently proven to be clinically effective in treating symptoms of Parkinson's disease, with potential to be beneficial in other central nervous system diseases as well. Per the agreement, Shire has been granted an exclusive option, pending completion of certain preclinical studies, to license worldwide development and commercial rights to the A2A program. Heptares has received an upfront payment and is eligible, if Shire exercises the option, to an option exercise payment, future milestone payments and royalties on product sales. Additional details and financial terms were not disclosed.


Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.